Circulating miRNAs. ICORG 10-11, V2
To identify a panel of circulating miRNA markers which could help identify those breast cancer patients who are most likely to respond well to neoadjuvant and adjuvant chemotherapy, and indeed serve as an overall prognostic factor and stratify patients into risk categories which would further guide their management. Similarly, the investigators aim to identify a panel of circulating miRNA markers which could monitor patient's response to chemotherapy and hormonal therapies. Ideally a suitable panel of markers would show significant changes in expression level in good-responders whilst little or no change would be observed in miRNA expression in non-responders.
Newly Diagnosed Breast Cancer
Recurrent Breast Cancer
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Circulating miRNAs: Novel Breast Cancer Biomarkers and Their Use for Guiding and Monitoring Response to Chemotherapy|
- Relationship between changes in a patients circulating miRNA expression levels over the course of their systemic therapy, and their response to that treatment. [ Time Frame: up to week 66-92 ] [ Designated as safety issue: No ]Patients' response to treatment will be determined using 3 standard parameters: clinical, radiological and pathological responses.
- Correlation of systemic miRNA levels with standard biomarkers of response [ Time Frame: up to week 66-92 ] [ Designated as safety issue: No ]Standard bio markers of response include serum CEA and Ca15-3 levels
- Relationship between circulating miRNA profiles and patients' intrinsic subtype of breast cancer [ Time Frame: up to week 66-92 ] [ Designated as safety issue: No ]
- Relationship between miRNA expression levels and other existing clinicopathological parameters. [ Time Frame: up to week 66-92 ] [ Designated as safety issue: No ]Other existing clinicopathological parameters include: ER, PR and HER2 status, stage of disease,histological grade and size of the tumour, and the Nottingham Prognostic Index.
|Study Start Date:||May 2011|
|Estimated Primary Completion Date:||June 2017 (Final data collection date for primary outcome measure)|
Newly diagnosed breast cancer patients
All newly diagnosed breast cancer patients who are scheduled to undergo neoadjuvant chemotherapy will be recruited and enrolled into this study at the time of diagnosis, pending gaining informed consent.
Recurrent breast cancer patients
All patients with a history of breast cancer who represent with disease recurrence or progression, and are commencing up-front hormonal therapy or chemotherapy, will also be recruited and enrolled.
- To identify a panel of miRNAs, detectable in the circulation, which are altered in breast cancer patients
- To identify specific combinations of miRNAs ('signatures') which associate with breast cancer intrinsic subtypes, and thereby could aid in prognostication and treatment planning on an individual patient basis.
1. To determine if systemic miRNA analysis can be used as a biomarker for monitoring response to chemotherapy, in the neoadjuvant setting and in patients who present with breast cancer recurrence and are treated with upfront chemotherapy
This is a prospective cohort studies, involving two study cohorts:
Cohort 1: Newly diagnosed breast cancer patients, Cohort 2: Recurrent breast cancer patients
- 1st (baseline) blood sample at presentation before commencing neoadjuvant (cohort 1) or systemic (cohort 2) treatment.
- 2nd blood sample midway through their chemotherapy treatment (after 2nd cycle if they are enrolled in a 4 cycle regimen, or after 4th cycle if they are prescribed an 8 week regimen).
- 3rd blood sample post-chemotherapy and before surgery (if applicable).
- 4th blood sample 2-4 weeks after surgery, or after last blood sampling if surgery is not envisaged
- 5th blood sample 12-18 month after surgery or after 3rd blood sampling if surgery is not envisaged.
GUH only: Tissue samples will be taken at time of biopsy and/or at time of surgery.
All samples will be processed for miRNA quantification - a panel of 9 cancer-specific miRNAs will be measured in each sample, and the change in each patient's miRNA expression levels monitored over the course of their treatment.
Blood samples will be processed for miRNA analysis, which involves:
- Lysis using Trizol
- RNA isolation
- Assessing concentration and integrity of RNA using Nanodrop spectrophotometry
- cDNA synthesis (using miRNA specific stem loop primers)
- PCR amplification and relative quantification (using miRNA specific probes)
Please refer to this study by its ClinicalTrials.gov identifier: NCT01722851
|Bon Secours Hospital||Recruiting|
|Contact: Contact Person 021-4542807|
|Principal Investigator: Conleth Murphy, Dr|
|Contact: Contact Person 01-8093760|
|Principal Investigator: Arnold Hill, Prof|
|St James's Hospital||Recruiting|
|Contact: Contact person 01 410 3000|
|Principal Investigator: John Kennedy, Dr|
|University Hospital Galway||Recruiting|
|Contact: Contact Person (0)91 524222|
|Principal Investigator: Michael J Kerin, Prof|
|Letterkenny General Hospital||Recruiting|
|Contact: Contact Person 074-9123798|
|Principal Investigator: Karen Duffy, Dr|
|Sligo General Hospital||Recruiting|
|Contact: Contact Person (071) 9171111|
|Principal Investigator: Michael Martin, Dr|